Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pepgen Inc (PEPG)

Pepgen Inc (PEPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 385,983
  • Shares Outstanding, K 32,354
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,630 K
  • 60-Month Beta 1.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.57
Trade PEPG with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.72
  • Number of Estimates 4
  • High Estimate -0.64
  • Low Estimate -0.85
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.22 +14.34%
on 04/22/24
15.34 -23.86%
on 04/01/24
-3.02 (-20.54%)
since 03/28/24
3-Month
7.30 +60.00%
on 01/30/24
17.51 -33.30%
on 03/05/24
+4.43 (+61.10%)
since 01/29/24
52-Week
3.72 +213.98%
on 11/10/23
17.51 -33.30%
on 03/05/24
-3.41 (-22.60%)
since 04/28/23

Most Recent Stories

More News
PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why

PepGen, Inc. (PEPG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through...

PEPG : 11.68 (-2.10%)
Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going

PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our...

PEPG : 11.68 (-2.10%)
Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength

PepGen, Inc. (PEPG) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

PEPG : 11.68 (-2.10%)
Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High?

The consensus price target hints at a 50.4% upside potential for PepGen, Inc. (PEPG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

PEPG : 11.68 (-2.10%)
What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing'

PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our...

PEPG : 11.68 (-2.10%)
Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 68.1% in PepGen, Inc. (PEPG). While the effectiveness of this highly sought-after metric is questionable, the positive...

PEPG : 11.68 (-2.10%)
PepGen (NASDAQ: PEPG) Shares Phase 1 Clinical Trial Results of PGN-EDO51 Showing Positive Data in Treating Duchenne Muscular Dystrophy

PepGen, Inc. (NASDAQ: PEPG) is engaged as a clinical-stage biotechnology company, which is focused on the research and development of

PEPG : 11.68 (-2.10%)
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments

BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide...

PEPG : 11.68 (-2.10%)
It’s Time To Nibble On These Two Recent IPOs 

It’s hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen...

BLCO : 15.12 (+2.23%)
PEPG : 11.68 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 13.65
2nd Resistance Point 13.22
1st Resistance Point 12.45
Last Price 11.68
1st Support Level 11.25
2nd Support Level 10.82
3rd Support Level 10.05

See More

52-Week High 17.51
Fibonacci 61.8% 12.24
Last Price 11.68
Fibonacci 50% 10.61
Fibonacci 38.2% 8.99
52-Week Low 3.72

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar